This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Min, K. T. Articles by Yang, J. Search for Related Content PubMed PubMed Citation Articles by Min, K. T. Articles by Yang, J.

---

GENERAL ARTICLES

Nondepolarizing Neuromuscular Blockers Inhibit the Serotonin-Type 3A Receptor Expressed in Xenopus Oocytes

Kyeong T. Min, MD^*, Christopher L. Wu, MD^*, and Jay Yang, PhD, MD^*,

*Departments of Anesthesiology and Pharmacology/Physiology, University of Rochester Medical Center, Rochester, New York

Address correspondence and reprint requests to Jay Yang, Department of Anesthesiology; Box 604, University of Rochester Medical Center, 601 Elmwood Ave., Rochester, NY 14642. Address e-mail to jyang{at}anes.rochester.edu

Molecular cloning and sequence comparison indicates a high degree of structural homology between muscle nicotinic acetylcholine (nACh) and serotonin-type 3 (5-HT_3A) receptors, both members of the direct ligand-gated family of ion channels. Because of the structural similarities and common evolutionary origin of these receptors, neuromuscular blockers (competitive nACh antagonists) may demonstrate pharmacologic cross talk and exhibit attributes of 5-HT_3A receptor antagonists. We examined six clinically-used neuromuscular blockers for their ability to antagonize currents flowing through the 5-HT_3A receptors in voltage clamped Xenopus oocytes. The neuromuscular blockers reversibly inhibited the 5-HT_3A receptor-gated current in the rank order potency of (IC50 mean ± SEM): d-tubocurarine (0.046 ± 0.003 µM), atracurium (0.40 ± 0.03 µM), mivacurium (15.1 ± 2.93 µM), vecuronium (16.3 ± 2.24 µM), and rocuronium (19.5 ± 2.31 µM). Gallamine was essentially inactive as a 5-HT_3A receptor antagonist with an extrapolated IC50 of 1170 µM. We demonstrate that drugs classically known as competitive nACh receptor antagonists also block 5-HT_3A receptors. It is likely that certain neuromuscular blockers share pharmacological properties with 5-HT_3A receptor antagonists, such as a reduction in postoperative nausea and vomiting. With careful drug selection, pharmacological cross talk could potentially be used to minimize polypharmacy and optimize patient management.

Implications: Muscle nicotinic acetylcholine and serotonin-type 3A (5-HT_3A) receptors are similar. Therefore neuromuscular relaxants may block 5-HT_3A receptors. Our pharmacological study demonstrates that neuromuscular relaxants, as with ondansetron, are 5-HT_3A receptor antagonists. It is likely that certain neuromuscular relaxants exhibit ondansetron-like clinical properties, such as reduction in postoperative nausea and vomiting.

This article has been cited by other articles:

				M. Paul, R. Callahan, J. Au, C. H. Kindler, and C. S. Yost Antiemetics of the 5-Hydroxytryptamine 3A Antagonist Class Inhibit Muscle Nicotinic Acetylcholine Receptors Anesth. Analg., September 1, 2005; 101(3): 715 - 721. [Abstract] [Full Text] [PDF]

				L. Gyermek and J. Yang Muscle Relaxants and 5-HT3 Receptors Response Anesth. Analg., October 1, 2000; 91(4): 1039 - 1039. [Full Text] [PDF]